Loading stock data…
Voyager Therapeutics, Inc. (VYGR)
$3.10+0.01 (+0.32%)
Market ClosedLast close Jul 24
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Voyager Therapeutics, Inc. in the Healthcare sector is trading at $3.10 with a market capitalization of $218M. Wall Street consensus targets $14.89 (9 analysts), implying a +380.3% move over the next 12 months. The stock is currently near its 52-week low of $2.88, remaining 22.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +380.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 31) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.59M↓ | $15.34M↑ | $13.37M↑ | $5.20M↓ | $6.47M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$30.27M↓ | -$29.93M↑ | -$30.59M↑ | -$36.63M↓ | -$34.69M |
| Net Income | -$27.94M↓ | -$27.43M↑ | -$27.89M↑ | -$33.38M↓ | -$31.02M |
Peer Comparison
JNJUNHPFE
Fundamentals
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$217.52M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.26
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-67.16%
Volume
Today's trading volume
474,212
Recent News
Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?
Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London.
Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money
On the June 30 episode of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer about Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company he wanted to hold for the long haul. Cramer’s response was a shrug wrapped around a birthday card. “Only because you told me that can I encourage you ... Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money
Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside
Voyager Therapeutics Inc. (NASDAQ:VYGR) is one of the 10 best stocks under $10 offering more than 50% upside. Back on June 1, Voyager Therapeutics Inc. (NASDAQ:VYGR) received FDA approval for VY1706, a gene therapy for Alzheimer’s that targets extracellular and intracellular tau. The company had previously submitted an Investigational New Drug (IND) application, and this […]
Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs
Voyager Therapeutics Inc (NASDAQ:VYGR) is one of the best gene therapy stocks to buy in 2026. While the stock has risen only a modest 30% over the past year, analysts believe it can explode more than 250% over the next 12 months as the company advances its drug programs. On May 13, Voyager Therapeutics announced […]